Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition that causes inflammation in the central nervous system, particularly affecting the optic nerves and spinal cord. Though uncommon, it can lead to serious disability if left untreated, making early diagnosis and management essential for preserving vision and mobility.
Understanding the Numbers: Who Gets NMOSD?
Neuromyelitis optica spectrum disorder is considered a rare condition, but understanding how many people it affects helps paint a picture of its impact. The numbers vary depending on the region and population studied, but estimates suggest that between 0.3 and 4.4 people per 100,000 are affected by this condition. In practical terms, this means somewhere between 1,000 and 14,600 people in the United States live with NMOSD, while worldwide estimates range from 24,000 to 350,600 cases.[2]
However, these numbers may not tell the full story. Because NMOSD is often misdiagnosed as multiple sclerosis initially, the true number of people living with the condition might be higher than reported. As awareness grows and diagnostic testing improves, healthcare professionals are identifying more cases that previously went unrecognized or were incorrectly classified.[3]
The condition shows a strong preference for certain groups of people. Women are disproportionately affected, making up about 80% to 90% of all cases. This striking gender difference means that for every man diagnosed with NMOSD, there are between four and nine women facing the same diagnosis.[2][4]
Age also plays a role in when NMOSD typically appears. Most people receive their diagnosis between the ages of 30 and 40, though the condition can strike at any age. The median age of onset is around 40 years. Children are rarely affected, representing only about 5% of all cases, making pediatric NMOSD particularly uncommon.[2][4]
Geographic and ethnic patterns reveal important insights about who is most vulnerable to NMOSD. People of African descent, especially those of African Caribbean heritage, experience higher rates of the condition. The Caribbean island of Martinique holds the distinction of having the highest concentration of cases relative to its population size, with approximately 10 people per 100,000 affected. Asian populations also show higher prevalence rates, with estimates suggesting a two- to three-fold increase compared to other ethnic groups.[2][4]
What Causes NMOSD?
The root cause of neuromyelitis optica spectrum disorder remains unknown, but scientists have made significant progress in understanding what happens in the body when the condition develops. NMOSD is classified as an autoimmune disease, which means the body’s immune system mistakenly attacks its own tissues instead of protecting them from outside threats.[1]
In most cases of NMOSD, the immune system produces abnormal proteins called antibodies that target a specific structure in the nervous system. These antibodies, known as aquaporin-4 immunoglobulin G or AQP4-IgG, attack a protein called aquaporin-4 that helps transport water across cell membranes. This protein is abundantly present on specialized brain cells called astrocytes, particularly at their foot-like extensions that connect to blood vessels in the brain and spinal cord.[1][5]
When these antibodies bind to the aquaporin-4 protein, they trigger a cascade of damaging events. The immune system launches an inflammatory attack that damages the astrocytes, which are essential support cells for the nervous system. This inflammation spreads, affecting the protective coating around nerve fibers called myelin, ultimately leading to damage of the nerves themselves. The resulting injury disrupts the normal transmission of signals through the nervous system, producing the various symptoms associated with NMOSD.[12]
Interestingly, not everyone with NMOSD tests positive for AQP4-IgG antibodies. Studies show that these antibodies are present in up to 80% of people with NMOSD, leaving a significant portion who are seronegative, meaning the antibodies don’t appear in their blood tests. Some of these seronegative individuals may have antibodies against a different protein called myelin oligodendrocyte glycoprotein (MOG), which represents a related but distinct condition.[4]
Certain triggers may set off the development of NMOSD in susceptible individuals. The condition sometimes appears following an infection, suggesting that exposure to certain viruses or bacteria might activate the immune system in ways that lead to NMOSD. There is also evidence that NMOSD can occur alongside other autoimmune conditions, indicating shared mechanisms in how the immune system malfunctions.[1][6]
Family history plays a minor role in NMOSD risk. Only about 3% of people with NMOSD have a relative who also has the condition. However, roughly half of those diagnosed have either a personal history of another autoimmune disorder or a family member with such a condition, suggesting genetic factors may create vulnerability to autoimmune diseases in general rather than NMOSD specifically.[5][13]
Risk Factors: Who Is More Vulnerable?
Understanding risk factors helps identify who might be more susceptible to developing NMOSD, though having these risk factors doesn’t guarantee someone will develop the condition. Gender stands out as the most prominent risk factor. Being female increases the likelihood of developing NMOSD by approximately four to nine times compared to being male. This dramatic difference suggests hormonal or genetic factors related to biological sex may influence disease development.[2][4]
Ethnicity and racial background also influence risk. People of Asian descent face higher odds of developing NMOSD compared to other populations. Similarly, individuals of African ancestry, particularly those with African Caribbean heritage, show increased vulnerability to the condition. In contrast, while white individuals can certainly develop NMOSD, they appear to have somewhat lower rates overall.[2][4]
Age represents another consideration, though NMOSD can occur at any point in life. The condition most commonly emerges during middle age, with peak onset occurring between ages 30 and 40. However, cases in children, teenagers, and older adults are also documented, so age alone shouldn’t rule out the possibility of NMOSD when symptoms suggest it.[2][4]
Having other autoimmune conditions may increase susceptibility to NMOSD. People who already live with autoimmune diseases such as lupus, thyroid disorders, or other conditions where the immune system attacks the body’s own tissues show higher rates of NMOSD. This pattern suggests shared underlying vulnerabilities in immune system regulation.[5][6]
Recognizing the Symptoms
The symptoms of NMOSD can be severe and life-altering, affecting how people see, move, and experience sensation. These symptoms typically appear suddenly during disease attacks, which are also called relapses or flare-ups. Understanding the range of possible symptoms helps people and their healthcare providers recognize when NMOSD might be present.[1]
Vision problems are among the most common and concerning symptoms of NMOSD. The condition causes optic neuritis, which is inflammation of the optic nerves that connect the eyes to the brain. This inflammation can produce several troubling visual symptoms. People may experience blurred or foggy vision that makes it difficult to see clearly. Colors may appear washed out or difficult to distinguish. Some people notice eye pain, particularly when moving their eyes. In more severe cases, vision can be partially or completely lost in one or both eyes. What makes NMOSD particularly concerning is that it can affect both eyes simultaneously, unlike multiple sclerosis which typically affects one eye at a time.[1][4]
When NMOSD affects the spinal cord, a condition called transverse myelitis, it produces a different set of symptoms related to movement, sensation, and bodily functions. Weakness in the arms or legs can range from mild difficulty with fine movements to severe paralysis that prevents walking. Numbness, tingling, or complete loss of sensation can occur in various parts of the body. Some people experience painful muscle spasms where muscles suddenly and involuntarily tighten, causing significant discomfort.[1][6]
Bladder and bowel problems frequently accompany spinal cord involvement in NMOSD. People may struggle to empty their bladder completely, experience urgent needs to urinate, or lose control of urination. Similarly, bowel function can be affected, leading to constipation or incontinence. These issues profoundly impact quality of life and often require specific management strategies.[1][6]
When NMOSD affects the brainstem, a part of the brain that controls many automatic functions, unusual symptoms can appear. Persistent hiccups that don’t respond to typical remedies are surprisingly common and can be quite distressing. Uncontrollable nausea and vomiting may occur without an obvious cause. These symptoms, while seeming unrelated to neurological disease, can be important clues pointing toward NMOSD, especially when they appear alongside vision or spinal cord problems.[1][4]
Sexual function can also be impaired in NMOSD, causing difficulty achieving erections or reaching orgasm. Sleep disturbances are common, with people struggling to fall asleep or stay asleep through the night. Fatigue is particularly troublesome, with many people experiencing profound exhaustion that doesn’t improve with rest.[6][15]
The pattern of symptoms in NMOSD typically follows a relapsing course. Symptoms develop over hours or days during an attack, usually lasting days to weeks before gradually improving. Some people recover well from attacks with appropriate treatment, while others experience incomplete recovery that leaves lasting impairment. Between attacks, people may feel relatively well, or they may continue experiencing residual symptoms from previous relapses.[6]
Prevention: Can NMOSD Be Prevented?
Unfortunately, there is no known way to prevent the initial development of neuromyelitis optica spectrum disorder. Because the underlying cause remains unclear and the condition appears to result from a complex interaction between genetic susceptibility and unknown environmental triggers, strategies for primary prevention haven’t been identified.[1]
However, once someone has been diagnosed with NMOSD, prevention takes on a different meaning: preventing future attacks or relapses. This form of prevention is crucial because each attack can cause additional permanent damage to the nervous system, accumulating disability over time. Without preventive treatment, the likelihood of experiencing another attack within one year is approximately 60%, and the consequences can be severe. After five years without treatment, about 40% of people may be legally blind in at least one eye, and 20% may require a walker or other mobility assistance.[4][11]
The main approach to prevention in NMOSD involves long-term immunosuppressive therapy, which means taking medications that reduce the activity of the immune system. This helps prevent the abnormal immune attacks that damage the nervous system. Several medications have been used for this purpose, including traditional immunosuppressants like azathioprine and mycophenolate mofetil, as well as newer targeted therapies such as rituximab. More recently, specific medications have been approved specifically for preventing NMOSD relapses, including eculizumab, ravulizumab, inebilizumab, and satralizumab.[7][11]
Starting preventive treatment as soon as possible after diagnosis is important because it can significantly reduce the risk of future attacks and the disability they cause. Healthcare providers work with each person to determine which preventive medication is most appropriate based on individual circumstances, including the presence of AQP4-IgG antibodies, previous attack severity, and other health considerations.[7]
While medications form the backbone of prevention, general health measures also support overall wellbeing for people with NMOSD. Vaccinations should be completed before starting certain immunosuppressive treatments, as some medications make vaccines less effective or increase infection risk. Regular follow-up with healthcare providers helps monitor for signs of relapse and allows for adjustments to treatment as needed.[8]
How NMOSD Changes Normal Body Functions
To understand how NMOSD affects the body, it helps to know some basics about the nervous system. The nervous system consists of the brain, spinal cord (together called the central nervous system), and the network of nerves throughout the body (the peripheral nervous system). These components work together to transmit information using electrical and chemical signals that travel through specialized cells called neurons.[2]
Each neuron has a long extension called an axon, which carries electrical signals like a wire carrying electricity. Surrounding the axon is a protective coating called myelin, made of fatty compounds that insulate the axon and help electrical signals travel quickly and efficiently. Think of myelin like the plastic insulation around an electrical cord—it keeps the signal strong and prevents it from leaking out or being disrupted.[2]
NMOSD is classified as a demyelinating disease, meaning it damages this myelin coating. Supporting the neurons are specialized cells called astrocytes, which act like the brain’s maintenance crew. They help provide nutrients to neurons, maintain the right chemical environment, and form an important barrier called the blood-brain barrier that protects the brain from harmful substances in the bloodstream.[2][12]
Astrocytes have high concentrations of aquaporin-4, a protein that functions as a water channel, helping regulate fluid balance in the brain and spinal cord. In NMOSD, the immune system produces antibodies (AQP4-IgG) that specifically target this aquaporin-4 protein. When these antibodies bind to aquaporin-4 on astrocytes, they trigger a destructive immune response.[9][12]
The attack unfolds through multiple mechanisms. The binding of antibodies to aquaporin-4 activates parts of the immune system called complement, a group of proteins that normally help destroy bacteria and viruses. In NMOSD, this complement system mistakenly attacks the body’s own astrocytes, punching holes in their membranes and causing them to die. The death and dysfunction of astrocytes creates a cascade of problems throughout the affected area of the nervous system.[12]
As astrocytes die, they can no longer support nearby neurons properly. The protective blood-brain barrier becomes damaged, allowing more immune cells and antibodies to flood into the brain and spinal cord tissue. White blood cells, particularly neutrophils and other inflammatory cells, infiltrate the affected areas and release destructive substances. This creates intense inflammation that spreads the damage further.[12]
The inflammation and astrocyte damage lead to destruction of myelin, the protective coating around axons. Without myelin, electrical signals traveling through neurons slow down or stop entirely, like electricity trying to travel through a damaged wire. If damage continues, the axons themselves can be injured or severed, causing permanent loss of function. Neurons may die because they no longer receive proper support from astrocytes or because direct inflammatory damage destroys them.[2][12]
NMOSD shows a particular preference for attacking certain parts of the nervous system. The optic nerves, which transmit visual information from the eyes to the brain, are frequently targeted, resulting in vision problems. The spinal cord is another common site of attack, producing problems with movement, sensation, and control of bladder and bowel function. Parts of the brainstem, which controls automatic functions like breathing and digestion, can also be affected, leading to symptoms like hiccups and nausea.[1][12]
The location and extent of damage determine which symptoms appear during an attack. Damage to the optic nerves causes vision loss. Injury to the spinal cord at different levels produces varying patterns of weakness, numbness, and loss of bodily function control depending on which spinal segments are affected. Brainstem involvement produces its characteristic symptoms of hiccups, nausea, and vomiting. The severity of symptoms relates to how extensively the tissue is damaged during each attack.[3]
After an attack subsides, some repair can occur. Inflammation gradually resolves as the immune assault diminishes, especially with treatment. Some myelin can be rebuilt, and surviving neurons may partially compensate for damaged connections by forming new pathways. However, if astrocytes and neurons were killed during the attack, they typically cannot be replaced, leading to permanent damage and lasting disability. This is why preventing attacks through immunosuppressive medication is so important—it helps avoid accumulating irreversible damage over time.[12]
